References
- Nowell PC. The clonal evolution of tumor cell populations. Science194(4260), 23–28 (1976).
- Dulbecco R. A turning point in cancer research: sequencing the human genome. Science231(4742), 1055–1056 (1986).
- Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature409(6822), 860–921 (2001).
- Tiacci E, Trifonov V, Schiavoni G et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med.364(24), 2305–2315 (2011).
- Ley TJ, Mardis ER, Ding L et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature456(7218), 66–72 (2008).
- Puente XS, Pinyol M, Quesada V et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature475(7354), 101–105 (2011).
- Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature476(7360), 298–303 (2011).
- Pasqualucci L, Trifonov V, Fabbri G et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet.43(9), 830–837 (2011).
- Chapman MA, Lawrence MS, Keats JJ et al. Initial genome sequencing and analysis of multiple myeloma. Nature471(7339), 467–472 (2011).
- Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
- Anderson K, Lutz C, Van Delft FW et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature469(7330), 356–361 (2011).
- Notta F, Mullighan Cg, Wang Jc et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature469(7330), 362–367 (2011).
- Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood106(1), 296–303 (2005).
- Fonseca R, Blood E, Rue M et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood101(11), 4569–4575 (2003).
- Shaughnessy JD Jr, Zhan F, Burington BE et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood109(6), 2276–2284 (2007).
- Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood106(13), 4050–4053 (2005).
- Richardson PG, Blood E, Mitsiades CS et al. A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood108(10), 3458–3464 (2006).
- Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol.86(1), 57–65 (2011).
- Zhu YX, Braggio E, Shi CX et al. Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood doi:10.1182/blood-2011-05-356063 (2011) (Epub ahead of print).
- Quach H, Ritchie D, Stewart AK et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia24(1), 22–32 (2010).
- Li S, Pal R, Monaghan SA et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood117(19), 5157–5165 (2011).
- Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood112(13), 4808–4817 (2008).
Websites
- The Cancer Genome Atlas. http://cancergenome.nih.gov
- Wellcome Trust Sanger Institute: Cancer Genome Project. www.sanger.ac.uk/genetics/CGP/Studies
- Multiple Myeloma Research Foundation. www.themmrf.org